Actelion’ Tracleer Receives EU Approval For Pediatric Formulation
Published: 06-Jul-2009
Tracleer also indicated to reduce digital ulcers in patients with systemic sclerosis and ongoing digital ulcer disease
Actelion' pediatric dispersible formulation of Tracleer (bosentan) for the treatment of pulmonary arterial hypertension (PAH) in children, has been approved in the EU.
Tracleer is an oral, dual endothelin receptor antagonist in WHO Functional Class III to improve exercise capacity and symptoms, and in WHO Functional Class II where some improvements have been shown. In the EU, Tracleer is also indicated to reduce the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcer disease.
The approval makes Tracleer the only PAH therapy with an approved pediatric formulation for treating children from two years of age, said the company.
Martine Clozel, Pediatrician and Chief Scientific Officer, Actelion, said: “Our team is very proud of this achievement. We decided very early in the development of Tracleer to devote time and effort to the development of a formulation adapted to the daily treatment of children suffering from PAH, even if it was representing a small population. It has been a long, but ultimately extremely rewarding journey, which had begun even before the first marketing authorization of Tracleer.”
Isaac Kobrin, MD and Head of Clinical Development at Actelion, added: “Having the approval of Tracleer, with an accurate dosing in a child-friendly form, is an important advancement in the treatment of PAH in children. After receiving approval in the EU, we will continue our regulatory filings in other countries to ensure that children can benefit from this pediatric formulation of Tracleer on a worldwide basis.”
Network Sites

Suppliers To This Sector
Browse A-Z
Solutions4Science
Temperature Mapping and Validation Services ...
Exploristics
Innovative Analysis Solutions for Data Exploration, Pharmacogenetics, Biomarkers and Exploratory Sta...
NeuroProof
Screening Services for Pre-Clinical Development of Neuro-Pharmaceuticals and Safety Pharmacology ...
DASGIP
Parallel Bioreactor Systems for the Cultivation of Bacterial, Phototrophic, Animal and Human Cells ...
BioKinetic Europe
Phase I/II Contract Research Organisation ...
Toxikon Europe
CRO Providing Preclinical Safety Studies for the Life Science Community ...
White Papers
Browse A-Z
GRACO's New FDA Pumps
The Graco 3150 3A sanitary pump is designed to meet the stringent sanitation requirements ...
GRACO's New Hydra-Clean
The Graco 3150 3A sanitary pump is designed to meet the stringent sanitation requirements ...
GRACO's New 1590 & 3150 Pumps
The Graco 3150 3A sanitary pump is designed to meet the stringent sanitation requirements ...
Water Treatment
From the control room to the downstream processing area and with an eye on utilities servi ...
Customer Testimonial – Astra Zeneca
From the control room to the downstream processing area and with an eye on utilities servi ...
Hygienic Processing
From the control room to the downstream processing area and with an eye on utilities servi ...


Delicious
Digg
Reddit
Stumble
LinkedIn
Mail sent successfully